CEO Today - May 2022

THE CEO INTERVIEW www.ceotodaymagazine.com 14 Tell us more about the work you’re doing on cannabinoids? Ananda Scientific is a leading research-focused Biotech company pioneering high-calibre clinical studies evaluating indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technology (licensed from Lyotropic Delivery Systems Ltd, in Jerusalem Israel), to make cannabinoids and other plant-derived compounds highly bioavailable, water-soluble, and shelf-life stable thereby producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-thecounter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion planned into additional markets such as the EU, China, Africa, and other countries in Asia. We are expanding our research base through multiple sponsored research agreements with universities to diversify our technology portfolio. Can you tell us what you think the future holds for the cannabinoid industry? We firmly believe the future of the cannabinoid industry lies in conducting well-designed placebocontrolled clinical studies to fully understand how cannabinoids work in the human body and to generate clinical evidence for an optimal therapeutic response for targeted disease indications. There is a lot of noise in the industry but very few companies are taking a science and pharmaceutical-based approach. Both the US Food and Drug Administration (FDA) and the US National Institute of Health (NIH) are clear in their approach to encouraging well designed clinical trials while advocating for a tightening of regulations around the nutraceutical use of cannabinoid products. What role will Adanda Scientific play in this? We see ourselves as an industry leader as we advance our clinical program to develop effective cannabinoid medicines based on our delivery technologies. Our goal is to provide new therapeutics to address significant medical needs. Research of pharmaceutical drugs is a long process, but we remain committed to our end goal of bringing effective cannabinoid medicines to the market. We have established a scientific research collaboration in Israel to continuously develop new innovative and cutting-edge drug delivery systems. Here in the US, we have focused on building a robust clinical development infrastructure with a broad blend of competencies to position Ananda Scientific as a leader in cannabinoid clinical trials with academic hospitals. We work with selective NIH funded Clinical Investigators as an industry partner pursuing well designed clinical research protocols that target indications where a strong scientific hypothesis exists. With five FDA approved phase 2 trials in progress, and two others in advanced stages of planning we are confident that we will be able to provide the necessary data that will help unleash the potential of cannabinoids. Ananda Scientific strives to be the face of American innovation in this field and as a team, our goal is to create something meaningful and lasting. What are you currently working on? Currently, we have five FDA Ananda Scientific strives to be the face of American innovation in this field and as a team, our goal is to create something meaningful and lasting. “ “

RkJQdWJsaXNoZXIy Mjk3Mzkz